SpringWorks Therapeutics, Inc. (SWTX) Financial Statements (2026 and earlier)

Company Profile

Business Address 100 WASHINGTON BOULEVARD
STAMFORD, CT 06902
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2025
MRQ
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:461,900662,600597,000432,700561,800327,652
Cash and cash equivalent69,751176,05367,490103,961147,089327,652
Short-term investments   524,722269,540361,395 
Other undisclosed cash, cash equivalents, and short-term investments392,149486,5474,78859,19953,316 
Receivables46,2385,930    
Inventory, net of allowances, customer advances and progress billings10,2123,103    
Inventory10,2123,103    
Other undisclosed current assets(137,885)(170,721)2,760(49,790)(48,402)3,709
Total current assets:380,465500,912599,760382,910513,398331,361
Noncurrent Assets
Operating lease, right-of-use asset6,9796,1444,6981,0101,944 
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization19,68017,94313,5713,1871,075795
Long-term investments and receivables158,123185,3418,98762,11357,207976
Long-term investments158,123185,3418,98762,11357,207976
Restricted cash and investments624613578565565540
Other noncurrent assets21,40514,8352,6482,7092,0021,159
Total noncurrent assets:206,811224,87630,48269,58462,7933,470
TOTAL ASSETS:587,276725,788630,242452,494576,191334,831
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities98,26072,96547,25228,80716,23511,607
Accounts payable12,2487,3968,0103,4291,3502,654
Accrued liabilities86,01265,56939,24225,37814,8858,953
Deferred revenue  4,1443,314   
Deferred rent credit      363
Other undisclosed current liabilities1,7301,0614831,1621,375 
Total current liabilities:99,99078,17051,04929,96917,61011,970
Noncurrent Liabilities
Long-term debt and lease obligation:    1291,359 
Liabilities, other than long-term debt6,18221,39921,001 164789
Deferred revenue  15,40316,233   
Deferred rent credit      789
Other liabilities     164 
Operating lease, liability6,1825,9964,7681291,359 
Other undisclosed noncurrent liabilities    (129)  
Total noncurrent liabilities:6,18221,39921,0011291,523789
Total liabilities:106,17299,56972,05030,09819,13312,759
Equity
Equity, attributable to parent481,104626,219558,192422,396557,058322,072
Common stock776554
Treasury stock, value(12,579)(4,141)(1,341)   
Additional paid in capital1,646,5371,524,1961,130,224715,216675,615395,097
Accumulated other comprehensive income (loss)3041,191(767)(312)41 
Accumulated deficit(1,153,165)(895,034)(569,930)(292,513)(118,603)(73,029)
Total equity:481,104626,219558,192422,396557,058322,072
TOTAL LIABILITIES AND EQUITY:587,276725,788630,242452,494576,191334,831

Income Statement (P&L) ($ in thousands)

3/31/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Revenues191,5895,447  35,000 
Cost of revenue
(Cost of Product and Service Sold)
(12,550)(422)    
Gross profit:179,0395,025  35,000 
Operating expenses(457,170)(348,038)(280,674)(173,468)(81,324)(59,239)
Other undisclosed operating loss      
Operating loss:(278,131)(343,013)(280,674)(173,468)(46,324)(59,239)
Nonoperating income26,00022,9476,1475461,3553,547
Investment income, nonoperating26,000  6981,330 
Other nonoperating income (expense)   (138)(152)253,547
Loss from continuing operations before equity method investments, income taxes:(252,131)(320,066)(274,527)(172,922)(44,969)(55,692)
Loss from equity method investments(6,000)(5,038)(2,890)(988)(605)(2,614)
Loss from continuing operations:(258,131)(325,104)(277,417)(173,910)(45,574)(58,306)
Loss before gain (loss) on sale of properties:(173,910)(45,574)(58,306)
Net loss attributable to parent:(258,131)(325,104)(277,417)(173,910)(45,574)(58,306)
Other undisclosed net income available to common stockholders, basic      7,729
Net loss available to common stockholders, diluted:(258,131)(325,104)(277,417)(173,910)(45,574)(50,577)

Comprehensive Income ($ in thousands)

3/31/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net loss:(258,131)(325,104)(277,417)(173,910)(45,574)(58,306)
Other comprehensive income (loss)    (353)41 
Comprehensive loss:(258,131)(325,104)(277,417)(174,263)(45,533)(58,306)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(887)1,958(455)   
Comprehensive loss, net of tax, attributable to parent:(259,018)(323,146)(277,872)(174,263)(45,533)(58,306)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: